Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2002 2
2003 2
2004 3
2005 11
2006 7
2007 4
2008 2
2009 4
2010 8
2011 21
2012 17
2013 16
2014 16
2015 15
2016 10
2017 7
2018 8
2019 5
2020 11
2021 6
2022 13
2023 9
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

178 results

Results by year

Filters applied: . Clear all
Page 1
Assessing antiviral treatment efficacy and risk factors for severe COVID-19 in kidney transplant recipients during the Omicron subvariant-dominant period: a retrospective study.
Sakaguchi T, Mitsuke A, Osako Y, Yamada Y, Takeyama H, Ogawa R, Takahashi K, Hirohata Y, Yamamoto S, Arima J, Fukumoto W, Sugita S, Inoguchi S, Matsushita R, Yoshino H, Tatarano S, Enokida H. Sakaguchi T, et al. Among authors: enokida h. BMC Nephrol. 2024 Apr 8;25(1):124. doi: 10.1186/s12882-024-03561-7. BMC Nephrol. 2024. PMID: 38589827 Free PMC article.
Validation of non-muscle-invasive bladder cancer risk stratification updated in the 2021 European Association of Urology guidelines.
Miyake M, Kitamura H, Nishimura N, Miyamoto T, Nakahama T, Fujii T, Matsumoto H, Matsuyama H, Yonemori M, Enokida H, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Nishiyama H, Fujimoto K; Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group. Miyake M, et al. Among authors: enokida h. BJUI Compass. 2023 Nov 3;5(2):269-280. doi: 10.1002/bco2.305. eCollection 2024 Mar. BJUI Compass. 2023. PMID: 38371197 Free PMC article.
Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.
Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group. Shiota M, et al. Among authors: enokida h. Ann Surg Oncol. 2024 Jun;31(6):3872-3879. doi: 10.1245/s10434-024-14999-2. Epub 2024 Feb 14. Ann Surg Oncol. 2024. PMID: 38353798
Enzalutamide versus Abiraterone Plus Prednisolone for Nonmetastatic Castration-Resistant Prostate Cancer: A Sub-Analysis from the ENABLE Study for PCa.
Mita K, Izumi K, Goriki A, Tasaka R, Hatayama T, Shima T, Kato Y, Kamiyama M, Inoue S, Tanaka N, Hoshi S, Okamura T, Yoshio Y, Enokida H, Chikazawa I, Kawai N, Hashimoto K, Fukagai T, Shigehara K, Takahara S, Kadono Y, Mizokami A. Mita K, et al. Among authors: enokida h. Cancers (Basel). 2024 Jan 24;16(3):508. doi: 10.3390/cancers16030508. Cancers (Basel). 2024. PMID: 38339260 Free PMC article.
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.
Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higasijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S. Yokomizo A, et al. Among authors: enokida h. Int J Urol. 2024 Apr;31(4):362-369. doi: 10.1111/iju.15371. Epub 2023 Dec 26. Int J Urol. 2024. PMID: 38148124 Clinical Trial.
Summary of the Clinical Practice Guidelines for Upper Tract Urothelial Carcinoma 2023 by the Japanese Urological Association.
Mori K, Hatakeyama S, Enokida H, Miyake H, Kikuchi E, Nishiyama H, Ichikawa T, Kamai T, Kaji Y, Kume H, Kondo T, Matsuyama H, Masumori N, Kawauchi A, Takenaka A, Uemura H, Eto M, Nonomura N, Fujii Y, Hinotsu S, Ohyama C. Mori K, et al. Among authors: enokida h. Int J Urol. 2024 Mar;31(3):194-207. doi: 10.1111/iju.15362. Epub 2023 Dec 19. Int J Urol. 2024. PMID: 38113344 Review.
Potential therapeutic target secretogranin II might cooperate with hypoxia-inducible factor 1α in sunitinib-resistant renal cell carcinoma.
Fukumoto W, Yoshino H, Horike SI, Kawakami I, Tamai M, Arima J, Kawahara I, Mitsuke A, Sakaguchi T, Inoguchi S, Meguro-Horike M, Tatarano S, Enokida H. Fukumoto W, et al. Among authors: enokida h. Cancer Sci. 2023 Oct;114(10):3946-3956. doi: 10.1111/cas.15914. Epub 2023 Aug 6. Cancer Sci. 2023. PMID: 37545017 Free PMC article.
Real-world treatment outcomes of patients with penile cancer in the Kyushu-Okinawa area of Japan in the pre-guideline era.
Yamaguchi T, Goya M, Higashijima K, Tobu S, Sato R, Tatarano S, Mukai S, Uemura KI, Tatsugami K, Tsubouchi K, Shida Y, Ishii T, Sakai H, Matsuoka H, Haga N, Eto M, Igawa T, Kamoto T, Enokida H, Shin T, Noguchi M, Fujimoto N, Saito S, Kamba T. Yamaguchi T, et al. Among authors: enokida h. Jpn J Clin Oncol. 2023 Aug 30;53(9):837-844. doi: 10.1093/jjco/hyad053. Jpn J Clin Oncol. 2023. PMID: 37282601
178 results